Integrilin
Executive Summary
Worldwide sales of Schering-Plough/Cor GPIIb/IIIa inhibitor were $42 mil. worldwide for the quarter. Integrilin is "now the U.S. leader in terms of the number of patients treated with this class of product," Schering says